Read more

June 13, 2024
2 min read
Save

Armored cells may form ‘an effective strategy’ in lymphoma after CAR-T fails

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • Eighty percent of heavily pretreated patients had an objective response to therapy.
  • No new safety signals observed using the novel CAR-T construct.

CHICAGO — Treatment of with an investigational chimeric antigen receptor T-cell therapy showed an acceptable safety profile and produced durable remissions among certain patients with non-Hodgin lymphoma.

Results from the first-in-human trial, presented at ASCO Annual Meeting, could end up influencing the expansion and effectiveness of huCART19-IL18, according to researchers.

Key findings from first-in-human trial of huCART19-IL18 infographic
Data derived from Svoboda J, et al. Abstract 7004. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago.

“When using armored [chimeric antigen receptor T cells in patients with lymphoma], targeting CD19 again after prior anti-CD19 CAR failure can be an effective strategy, resulting in durable responses,” Jakub Svoboda, MD, an associate professor of medicine at Abramson Cancer Center at University of Pennsylvania, said during a presentation. “Preliminary correlative studies suggest that [interleukin-18] enhances CAR T-cell therapy efficacy through intrinsic/extrinsic mechanisms.”

Background and methodology

A percentage of patients with relapsed or refractory non-Hodgin lymphomas do not receive long-term benefit from existing anti-CD19 CAR T cells.

Researchers attempted to enhance therapeutic efficacy by engineering huCART19-IL18 — a fourth generation 4-1BB anti-CD19 construct — armored with the ability to secrete the proinflammatory cytokine interleukin-18 (IL-18).

This study served as a first-in-human trial using huCART19-IL18 for CD19-positive B-cell malignancies. Eligible patients for the non-Hodgkin lymphoma cohort included those who experienced disease relapse after treatment with CD19-directed CAR-T or those who are refractory to CD19-directed CAR T-cell therapy.

As of Jan. 20, 2024, data cutoff date, 21 patients (median age, 64 years; range, 47-74; 76% men) with CD19-positive NHL received huCART19-IL18 infusions. The heavily pretreated study population — 38% of whom had diffuse large B-cell lymphoma — received a median 7 prior lines of therapy.

Safety served as the study’s primary endpoint, with secondary endpoints that included manufacturing feasibility and efficacy measurements.

Results, next steps

Of 21 study-evaluable patients, 18 (86%) received bridging therapy.

Researchers noted manufacturing of dose level 5 (3 × 108) as not being feasible due to an inability to achieve the target dose in four of six (67%) patients assigned to that dose level.

Researchers observed no study-related deaths in 21 patients eligible for safety evaluation.

Cytokine release syndrome occurred in 13 patients (62%): grade 1 for seven (33%), grade 2 for three (14%) and grade 3 for three (14%). Additionally, immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in three patients: grade 1 for two (10%) and grade 2 for one (5%).

Researchers evaluated efficacy in 20 patients with a median follow-up of 15 months (range, 3-31); they observed a 3-month overall response rate of 81% (90% CI, 60-93), with 52% complete remission (90% CI, 30-70) and 29% partial remission (90% CI, 14-51).

Researchers also observed a median duration of response of 10 months and median PFS of 8.7 months. Median OS has not been reached.

The most common grade 3 adverse events that could possibly be attributed to huCART19-IL18 included fatigue (38%), hypotension (29%) and low fibrinogen (23%).

Study investigators did not observe a correlation between cell dose and outcome; however, both response rates and mean expansion appeared higher in patients previously exposed to CD28 CAR than among patients who had prior 4-1BB CAR.

“To our knowledge, this is the first study using an armored CAR-T product secreting IL18,” Svoboda said.

“Peak huCART19-IL18 expansion and responses could be affected by prior CAR type,” he added. “We recommend expansion of dose level 1 and dose level 2.”